The European Union supports with 46.1 million euros a gene therapy for Parkinson's developed in Warsaw.
Always see our news on Google
The European Commission presents the Mazowiecki Bródnowski Hospital project as a STEP example of strategic investment in biotechnology, through funding from the European Regional Development Fund aimed at developing an innovative gene therapy for Parkinson's disease. The treatment under development uses a viral vector to deliver a therapeutic gene to specific areas of the brain, through advanced neurosurgery and real-time imaging, with the goal of slowing disease progression and improving the motor functions of patients.
The European Commission introduces the STEP project on gene therapy for Parkinson's disease developed at the Mazowiecki Bródnowski Hospital in Warsaw, funded with 46.1 million euros from the European Regional Development Fund and which it presents as an investment in European leadership in biotechnology and advanced medical research.
In short
The European Commission presents the project from the Mazowiecki Bródnowski Hospital in Warsaw as a STEP example of investment in biotechnology.
The project receives 46.1 million euros from the European Regional Development Fund.
The therapy under development uses a viral vector to deliver a therapeutic gene directly to specific areas of the brain.
Parkinson's disease is the second most common neurodegenerative disease in Europe, affecting approximately 1.2 million people.
The project funds advanced medical equipment, specialized infrastructure, and clinical research to bring the therapy closer to patients.
The European Commission published on May 7, 2026, a STEP story about the development of an innovative gene therapy for Parkinson's disease at the Mazowiecki Bródnowski Hospital in Warsaw. The project is funded with 46.1 million euros from the European Regional Development Fund and is presented as part of the EU's effort to strengthen Europe's position in biotechnology and advanced medical research.
Parkinson's disease is the second most common neurodegenerative disease in Europe, affecting approximately 1.2 million people. The project in Warsaw aims to develop a treatment that uses a viral vector to deliver a therapeutic gene directly to specific areas of the brain.
The procedure is based on advanced neurosurgical techniques and real-time imaging, so that the therapeutic gene can be delivered with a high degree of precision. The Commission specifies that the therapy aims to slow disease progression, improve motor functions, and increase the quality of life for patients.
The project aims to restore the production of key enzymes, and in the future could also reduce the need for high doses of medication. The Commission's formulation indicates a treatment under development, not a therapy already widely available to patients.
The European funding of 46.1 million euros will support advanced medical equipment, specialized infrastructure, and the clinical research necessary to bring these therapies closer to patients. The project is located in Poland, and the beneficiary is the Mazowiecki Bródnowski Hospital.
The Commission shows that the hospital has benefited from European funding for over 20 years. These investments have supported the modernization of medical infrastructure and the expansion of research capabilities, contributing to the international reputation of the center in neurosurgery and gene therapy.
The project is presented within the Platform for Strategic Technologies for Europe, STEP, as an example of investment in critical technologies. According to the Commission, the funding contributes to the broader goal of STEP to strengthen Europe's technological leadership in biotechnology.
STEP aims to stimulate EU investments in critical technologies and create synergies with European funding programs. The platform includes projects in the fields of digital, clean technologies, biotechnology, and defense, presented as relevant for innovation and Europe's competitiveness.
The Commission links the project from Warsaw to long-term European competitiveness in advanced medical technologies. In the case of Parkinson's disease, the practical stake is the development of a therapy capable of intervening in the mechanisms of the disease, not just managing symptoms through conventional treatments.
The Platform for Strategic Technologies for Europe, STEP, is the tool through which the EU aims to stimulate investments in critical technologies and strengthen European competitiveness. The platform focuses on sectors such as digital technologies, clean technologies, biotechnology, and defense.
The European Regional Development Fund finances investments that support regional development, competitiveness, and infrastructure. In the case of the project at the Mazowiecki Bródnowski Hospital, European support is directed towards equipment, specialized infrastructure, and clinical research in the field of gene therapy.
The Mazowiecki Bródnowski Hospital is presented by the Commission as a center that has long benefited from European funding for the modernization of infrastructure and the development of medical research. The gene therapy project for Parkinson's is included in the series of STEP stories that illustrate how EU investments are used in technologies considered strategic for Europe.
Latest News
23:05
23:03
22:55
22:48
22:44
See more news
